Abstract P1-02-09: CDA screening technology for multi-ethnic group, early stage breast cancer screening

Author(s):  
H Tao ◽  
Y Lin ◽  
C Liu ◽  
J Dou ◽  
Y Sheng ◽  
...  
2015 ◽  
Vol 11 (01) ◽  
pp. 34
Author(s):  
Nienke A de Glas ◽  
Gerrit-Jan Liefers ◽  
◽  

As populations of developed countries are aging, the number of older women with breast cancer will strongly increase. Randomized controlled trials in breast cancer screening rarely included patients over the age of 68. As a consequence, there is no solid evidence for beneficial effects of breast cancer screening in older women. In a recent observational study, we showed that the implementation of screening in women aged 70–75 in the Netherlands resulted in a strong increase of the incidence of early-stage breast cancer, while the incidence of advanced stage breast cancer barely decreased. Hence, current data do not support population-based screening in women over the age of 70.


2019 ◽  
Vol 8 (6) ◽  
pp. 205846011985935
Author(s):  
Noel Miner ◽  
Kenneth Meng

Improvement in breast cancer screening technology has increased the detection of architectural distortion, which can often indicate underlying malignancy; however, there are also many benign causes of architectural distortion. We present a case of architectural distortion caused by cyst aspiration, representing a novel, benign cause.


2019 ◽  
Vol 92 (1103) ◽  
pp. 20190660 ◽  
Author(s):  
Almir GV Bitencourt ◽  
Carolina Rossi Saccarelli ◽  
Christiane Kuhl ◽  
Elizabeth A Morris

Breast cancer screening is widely recognized for reducing breast cancer mortality. The objective in screening is to diagnose asymptomatic early stage disease, thereby improving treatment efficacy. Screening recommendations have been widely debated over the past years and controversies remain regarding the optimal screening frequency, age to start screening, and age to end screening. While there are no new trials, follow-up information of randomized controlled trials has become available. The American College of Physicians recently issued a new guidance statement on screening for breast cancer in average-risk women, with similar recommendations to the U.S. Preventive Services Task Force and to European guidelines. However, these guidelines differ from those ofother American specialty societies. The variations reflect differences in the organizations’ values, the metrics used to evaluate screening results, and the differences in healthcare organization (individualized or state-organized healthcare). False-positive rates and overdiagnosis of biologically insignificant cancer are perceived as the most important potential harms associated with mammographic screening; however, there is limited evidence on their actual consequences. Most specialty societies agree that physicians should offer mammographic screening at age 40 years for average-risk women and discuss its benefits and potential harms to achieve a personalized screening strategy through a shared decision-making process.


2020 ◽  
Vol 19 (1) ◽  
Author(s):  
L. Ding ◽  
S. Jidkova ◽  
M. J. W. Greuter ◽  
K. Van Herck ◽  
M. Goossens ◽  
...  

Abstract Background Breast cancer (BC) is the most common cancer in women in the developed world. In order to find developing cancers in an early stage, BC screening is commonly used. In Flanders, screening is performed in and outside an organized breast cancer screening program (BCSP). However, the determinants of BC screening coverage for both screening strategies are yet unknown. Objective To assess the determinants of BC screening coverage in Flanders. Methods Reimbursement data were used to attribute a screening status to each woman in the target population for the years 2008–2016. Yearly coverage data were categorized as screening inside or outside BCSP or no screening. Data were clustered by municipality level. A generalized linear equation model was used to assess the determinants of screening type. Results Over all years and municipalities, the median screening coverage rate inside and outside BCSP was 48.40% (IQR: 41.50–54.40%) and 14.10% (IQR: 9.80–19.80%) respectively. A higher coverage rate outside BSCP was statistically significantly (P < 0.001) associated with more crowded households (OR: 3.797, 95% CI: 3.199–4.508), younger age, higher population densities (OR: 2.528, 95% CI: 2.455–2.606), a lower proportion of unemployed job seekers (OR: 0.641, 95% CI: 0.624–0.658) and lower use of dental care (OR: 0.969, 95% CI: 0.967–0.972). Conclusion Coverage rate of BC screening is not optimal in Flanders. Women with low SES that are characterized by younger age, living in a high population density area, living in crowded households, or having low dental care are less likely to be screened for BC in Flanders. If screened, they are more likely to be screened outside the BCSP.


Sign in / Sign up

Export Citation Format

Share Document